Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.83 |
| ▸ | PRKCG | P05129 | 1/20 | 0.83 |
| ▸ | PRKCB | P05771 | 1/20 | 0.83 |
| ▸ | PRKCA | P17252 | 1/20 | 0.83 |
| ▸ | PRKCH | P24723 | 1/20 | 0.83 |
| ▸ | PRKCI | P41743 | 1/20 | 0.83 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.83 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.83 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.83 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.83 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | GMNN | O75496 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10565337 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL15477735 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL10564175 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL1532761 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL2733343 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL10565746 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL417053 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL10602960 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL4320248 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG | |
| SCHEMBL2734265 | 1.00 | AKT1 (0.83) | AKT1LMNAALDH1A1PRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050037418-A1 | Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith | BIACORE AB (SE) | 2005-02-17 | — | — | US | claimed |
| US-20020019019-A1 | Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2002-02-14 | — | — | US | claimed |
| US-20260130930-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS | NAT JEWISH HEALTH (US) | 2026-05-14 | — | — | US | disclosed |
| US-12472193-B2 | Methods and compositions for treating and preventing respiratory related diseases and conditions with xylitol-headgroup lipid analogs | NATIONAL JEWISH HEALTH (US) | 2025-11-18 | — | — | US | disclosed |
| US-12384699-B2 | Self-assembled surfactant structures | CROSSTEK HOLDING COMPANY LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-11740235-B2 | Model-membrane-based lipid transfer assays and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230150841-A1 | Self-Assembled Surfactant Structures | DIAMOND GOLD INVESTORS, LLC | 2023-05-18 | — | — | US | disclosed |
| EP-4108319-A1 | SELF-ASSEMBLED SURFACTANT STRUCTURES | Crosstek Holding Company LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220273681-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS | NATIONAL JEWISH HEALTH | 2022-09-01 | — | — | US | disclosed |
| US-11401179-B2 | Self-assembled surfactant structures | DIAMOND GOLD INVESTORS, LLC (US) | 2022-08-02 | — | — | US | disclosed |
| US-11278556-B2 | Methods and compositions for treating and preventing respiratory related diseases and conditions with xylitol-headgroup lipid analogs | NATIONAL JEWISH HEALTH (US) | 2022-03-22 | — | — | US | disclosed |
| US-20110284456-A1 | Self-Assembled Surfactant Structures | DIAMOND GOLD INVESTORS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20080139520-A1 | Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase A2 | JAIN MAHENDRA K | 2008-06-12 | — | — | US | disclosed |
| EP-1188058-B1 | METHOD AND APPARATUS FOR ASSAYING A DRUG CANDIDATE TO ESTIMATE A PHARMACOKINETIC PARAMETER ASSOCIATED THEREWITH | BIACORE AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20050037418-A1 | Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith | BIACORE AB (SE) | 2005-02-17 | — | — | US | disclosed |
| US-6808938-B2 | Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith | BIACORE AB (SE) | 2004-10-26 | — | — | US | disclosed |
| WO-2002032395-A2 | SUSTAINED RELEASE DELIVERY SYSTEM AND USES THEREOF | ADVANCED DELIVERY SYSTEMS APS (DK) | 2002-04-25 | — | — | WO | disclosed |
| EP-1188058-A2 | METHOD AND APPARATUS FOR ASSAYING A DRUG CANDIDATE TO ESTIMATE A PHARMACOKINETIC PARAMETER ASSOCIATED THEREWITH | Biacore AB (SE) | 2002-03-20 | — | — | EP | disclosed |
| US-20020019019-A1 | Method and apparatus for assaying a drug candidate to estimate a pharmacokinetic parameter associated therewith | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2002-02-14 | — | — | US | disclosed |
| WO-2000079268-A2 | METHOD AND APPARATUS FOR ASSAYING A DRUG CANDIDATE TO ESTIMATE A PHARMACOKINETIC PARAMETER ASSOCIATED THEREWITH | BIACORE AB (SE) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139520-A1 | Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase A2 | PNLIP, PLA2G4B, PLA2G4A | AKT1 405/4885LMNA 4107/4885ALDH1A1 4160/4885 |
| US-20260130930-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS | PCTP, SGMS1, PHOSPHO1 | AKT1 1433/4885LMNA 683/4885ALDH1A1 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.